Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR. This is an ...

Tumor Mismatch Repair Immunohistochemistry and DNA MLH1 Methylation Testing of Patients With Endometrial Cancer Diagnosed at Age Younger Than 60 Years Optimizes Triage for Population-Level Germline ...

STOCKHOLM — A combination of pomalidomide (Pomalyst) and low-dose dexamethasone in double-refractory multiple myeloma has shown "highly significant" survival in a phase 3 trial. The results even ...